NCT02626962View on ClinicalTrials.gov

Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

July 22, 2021

Conditions
Uveal Melanoma
Interventions
DRUG

ipilimumab

Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)

DRUG

Nivolumab

Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks

Trial Locations (10)

Unknown

Hospital Son Espases, Palma de Mallorca

ICO Hospitalet, L'Hospitalet de Llobregat

H. Insular de Canarias, Las Palmas de Gran Canaria

Hospital La Paz, Madrid

H. U. Virgen de la Victoria, Málaga

Clínica Universidad de Navarra, Pamplona

H. U. Clínico de Santiago, Santiago

H.U. Virgen Macarena, Seville

Hospital General Universitario de Valencia, Valencia

H. C. U. de Valladolid, Valladolid

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Grupo Español Multidisciplinar de Melanoma

OTHER

NCT02626962 - Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter